Hsiao D. Lieu - Aug 11, 2021 Form 4 Insider Report for NGM BIOPHARMACEUTICALS INC (NGM)

Role: SVP, Chief Medical Officer
Signature: /s/ Valerie Pierce, Attorney-in-fact
Stock symbol: NGM
Transactions as of: Aug 11, 2021
Transactions value $: -$143,454
Form type: 4
Date filed: 8/13/2021, 04:27 PM
Next filing: Oct 7, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NGM	Common Stock	Sale	-$51.9K	-2.26K	-100%	$23.00^*	0	Aug 11, 2021	Direct	F1
transaction	NGM	Common Stock	Options Exercise	$96.5K	+8K		$12.06^*	8K	Aug 12, 2021	Direct
transaction	NGM	Common Stock	Sale	-$188K	-8K	-100%	$23.50^*	0	Aug 12, 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NGM	Stock Option (Right to Buy)	Options Exercise	$0	-8K	-4%	$0.00	192K	Aug 12, 2021	Common Stock	8K	$12.06	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 183 and 1,893 shares purchased through the Issuer's employee stock purchase plan on 11/13/2020 and 5/14/2021, respectively.
F2	The shares subject to the stock option vest over a four-year period measured from the grant date, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.